Clinical Trial Goal
To find out if the combination of epcoritamab, lenolidomise and tafasitamab is safe and works well to treat DLBCL, follicular lymphoma or high grad B-cell lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have any of the following that has relapsed or is refractory:
- DLBCL
- Follicular lymphoma, grade 3B
- High grade B-cell lymphoma
- Do not have lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Epcoritamab is a bispecific antibody that targets CD3 and CD20 on certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
Tafasitamab is a monoclonal antibody that targets CD19 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Lenalidomide is a drug that blocks growth of cancer cells.
Tafasitamab is a monoclonal antibody that targets CD19 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Epcoritamab – Given as a shot under your skin up to 1 time each week
- Lenalidomide – A pill that you take by mouth 1 time each day for 3 weeks
- Tafasitamab – Given as intravenous (IV) infusions up to 1 time each week
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat DLBCL, follicular lymphoma or high grad B-cell lymphoma that has relapsed or is refractory is new and unproven.
Locations
Sponsors
collaborator: Genmab, collaborator: Incyte Corporation, lead: Memorial Sloan Kettering Cancer Center
